Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 152,831 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Condition Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Antimicrobial-Prescribing in Emergency Departments

NCT03349567
View directory record Official record
Conditions
Anti-Bacterial Agents, Respiratory Tract Infections
Interventions
Audit-and-feedback
Behavioral
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Not applicable Interventional

Reverse Shoulder Replacement: Formal vs. Home Physiotherapy

NCT03430167
View directory record Official record
Conditions
Shoulder Arthropathy Associated With Other Conditions
Interventions
home therapy, formal therapy
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
61 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

NCT00782067
View directory record Official record
Conditions
Leukemia
Interventions
Midostaurin (PKC412)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 23, 2026, 3:34 PM EDT
Completed No phase listed Observational

Determine the Association Between the Level of SCI With Chronic Respiratory Symptoms, Measures of Pulmonary Function, and Respiratory Illness.

NCT00011336
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
West Roxbury, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 23, 2026, 3:34 PM EDT
Recruiting Phase 2 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Venetoclax, Obinutuzumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
15
States / cities
La Jolla, California • Atlanta, Georgia • Des Moines, Iowa + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 23, 2026, 3:34 PM EDT
Terminated Phase 3 Interventional Results available

Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients

NCT00784836
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BG9418 (interferon beta 1-a)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Detroit, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 23, 2026, 3:34 PM EDT
Completed No phase listed Observational

Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts

NCT00023036
View directory record Official record
Conditions
Sensorineural Hearing Loss, Cytomegalovirus Infection
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
Up to 99 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

NCT01904136
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Therapy-Related Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide, Fludarabine, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Natural Killer Cell Therapy, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 23, 2026, 3:34 PM EDT
Withdrawn Phase 1 Interventional

Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment

NCT01632436
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Pixantrone
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 23, 2026, 3:34 PM EDT
Recruiting No phase listed Observational

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

NCT06299436
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Pulmonary Hypertension, Right Heart Failure Due to Left Heart Failure
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

NCT02660736
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector, Placebo Liquid Auto-injector, Placebo Lyophilized DCC Pen injector
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy

NCT01009736
View directory record Official record
Conditions
Prostate Cancer
Interventions
tomato-soy juice, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 23, 2026, 3:34 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

NCT04452136
View directory record Official record
Conditions
Prostatic Neoplasms, Prostatic Diseases, Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
Interventions
68GA PSMA-HBED-CC
Drug
Lead sponsor
Jeanne Link
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 23, 2026, 3:34 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC

NCT02473536
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Stereotactic ablative radiation therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 23, 2026, 3:34 PM EDT
Terminated No phase listed Observational

Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis

NCT00883636
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Chronic Kidney Disease
Interventions
Cardiovascular Assessment, Renal Assessment, Genetic Evaluation
Other
Lead sponsor
Northwell Health
Other
Eligibility
6 Months to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

NCT01224171
View directory record Official record
Conditions
Crohn's Disease
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
40
States / cities
Lafayette, Colorado • Hamden, Connecticut • Gainesville, Florida + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 23, 2026, 3:34 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

NCT04606771
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib + Savolitinib, Savolitinib + Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Duarte, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 3:34 PM EDT
Completed No phase listed Observational

Reference Range Study for the Quantra QStat System

NCT04219371
View directory record Official record
Conditions
Coagulation Disorder
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Timeline
2020
U.S. locations
3
States / cities
Sandy Springs, Georgia • Raleigh, North Carolina • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 23, 2026, 3:34 PM EDT
Terminated No phase listed Observational

Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction

NCT01410071
View directory record Official record
Conditions
Sphincter of Oddi Dysfunction, Abdominal Pain
Interventions
Not listed
Lead sponsor
Wisconsin Center for Advanced Research
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 23, 2026, 3:34 PM EDT
Recruiting Phase 2 Interventional

Converting HR+ Breast Cancer Into an Individualized Vaccine

NCT03804944
View directory record Official record
Conditions
Breast Cancer
Interventions
Focal Radiation therapy, Pembrolizumab (200mg IV for 30 minutes, CDX-301
Radiation · Drug · Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Los Angeles, California • New York, New York • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 23, 2026, 3:34 PM EDT
Terminated Phase 4 Interventional Results available

Treprostinil Combined With Tadalafil for Pulmonary Hypertension

NCT01302444
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Portland, Maine • Boston, Massachusetts • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 23, 2026, 3:34 PM EDT
Recruiting Phase 2 Interventional

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

NCT04098744
View directory record Official record
Conditions
CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions
Artesunate vaginal insert, Placebo vaginal insert
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
25 Years to 100 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2 Interventional

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

NCT04360044
View directory record Official record
Conditions
Migraine, Cannabis, THC, CBD
Interventions
THC ~5%, CBD ~12%, THC ~5% and CBD ~12%, Sham Cannabis
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT01160744
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6), Cisplatin, Gemcitabine, Carboplatin (AUC 5)
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
38
States / cities
Scottsdale, Arizona • Tucson, Arizona • Corona, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 23, 2026, 3:34 PM EDT